Skip to main content
SpringerLink
Log in

Safety of Oral Ibandronate in the Treatment of Bone Metastases from Breast Cancer

Long-Term Follow-Up Experience

  • Short Communication
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

References

  1. Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 2000; 1: 43–51

    Article  PubMed  CAS  Google Scholar 

  2. Body JJ, editor. Tumor bone disease and osteoporosis in cancer patients. New York: Marcel Dekker, 2000

    Google Scholar 

  3. Coleman RE. Metastatic bone disease: clinical fractures, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165–76

    Article  PubMed  CAS  Google Scholar 

  4. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434–7

    PubMed  CAS  Google Scholar 

  5. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18

    Article  PubMed  Google Scholar 

  6. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676–9

    Article  PubMed  CAS  Google Scholar 

  7. Novartis Pharma. Zometa® (zoledronic acid). Prescribing information

  8. Novartis Pharma. Aredia® (pamidronate). Prescribing information

  9. Major P, Lipton A, Berenson J, et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 2000; 88: 6–14

    Article  PubMed  CAS  Google Scholar 

  10. Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59–65

    PubMed  CAS  Google Scholar 

  11. Atula S, Powles T, Paterson A, et al. Extended safety profile of oral clodronate after long-term use in primary breast cancer patients. Drug Saf 2003; 26: 661–71

    Article  PubMed  CAS  Google Scholar 

  12. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–5

    PubMed  CAS  Google Scholar 

  13. Body JJ, Diel IJ, Lichinitser M, et al. Intravenous ibandronic acid reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399–405

    Article  PubMed  Google Scholar 

  14. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004; 90: 1133–7

    Article  PubMed  CAS  Google Scholar 

  15. Body JJ, Diel IJ, Bell R, et al. Oral Ibandronic acid improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004; 111: 316–2

    Article  Google Scholar 

  16. Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004; 15: 743–50

    Article  PubMed  CAS  Google Scholar 

  17. Cancer Therapy Evaluation Program, Common Toxicity Criteria Version 2.0, DCTD, NCI, NIH, DHHS [online]. 1999 Apr 30 Available from URL: http://ctep.cancer.gov/reporting/CTC-3test.html

  18. Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219–24

    Article  PubMed  CAS  Google Scholar 

  19. Pecherstorfer M, Diel IJ, Bergström B. Long-term (4-year) safety of intravenous ibandronate in metastatic breast cancer: an open-label study [abstract]. Eur J Cancer Suppl 2004; 2: 130

    Article  Google Scholar 

  20. Body JJ, Diel I, Tripathy D, et al. Impact of ibandronic acid on bone pain in patients with metastatic bone disease from breast cancer [abstract no. A-34]. Support Care Cancer 2003; 11: 395–6

    Google Scholar 

  21. Tripathy D, Pecherstorfer M, Bartl R, et al. Reduction in risk of skeletal events with ibandronic acid in the treatment of metastatic breast cancer [abstract no. A-152]. Support Care Cancer 2003; 11: 427

    Google Scholar 

  22. Navarro RP, Morrow T, Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 2002; 15: 55–62

    PubMed  Google Scholar 

  23. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronic acid versus i.v. zoledronic acid and i.v. pamidronate in the treatment of metastatic bone disease in breast cancer [abstract no. 189P]. Ann Oncol 2004; 15Suppl. 3: iii50

    Google Scholar 

  24. Wardley A, Davidson N, Barrett-Lee P, et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869–76

    Article  PubMed  CAS  Google Scholar 

  25. O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933–7

    Article  PubMed  Google Scholar 

  26. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427–30

    PubMed  CAS  Google Scholar 

  27. Paterson AHG. Adjuvant bisphosphonate therapy: the future. Semin Oncol 2001; 28: 81–5

    Article  Google Scholar 

  28. Diel IJ, Solomayer EF, Costa S, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357–63

    Article  PubMed  CAS  Google Scholar 

  29. Green JR. Antitumor effects of bisphosphonates. Cancer Suppl 2003; 97: 840–7

    Google Scholar 

  30. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509–17

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The clinical trial and data analysis were conducted by Roche. The authors would like to thank Thomson Gardiner-Caldwell US for their editorial support.

Dr Tripathy has acted as a paid consultant for and has received honoraria and clinical research funding from Roche. Drs McLachlan, Cameron and Murray have acted as consultants for Roche.

Author information

Authors and Affiliations

  1. St Vincent’s Hospital, PO Box 2900, VIC 3065, Melbourne, Victoria, Australia

    Sue-Anne McLachlan

  2. Western General Hospital, Edinburgh, Scotland

    David Cameron

  3. Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia

    Robin Murray

  4. Southwestern Medical Center, University of Texas, Dallas, Texas, USA

    Debu Tripathy

  5. Hoffmann-La Roche Inc., Nutley, New Jersey, USA

    Bengt Bergström

Authors
  1. Sue-Anne McLachlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robin Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Debu Tripathy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bengt Bergström
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sue-Anne McLachlan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McLachlan, SA., Cameron, D., Murray, R. et al. Safety of Oral Ibandronate in the Treatment of Bone Metastases from Breast Cancer. Clin. Drug Investig. 26, 43–48 (2006). https://doi.org/10.2165/00044011-200626010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626010-00006

Keywords

Search

Navigation